Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
This study is testing if adding a drug called pembrolizumab to standard chemotherapy helps prevent lung cancer from returning after surgery. By using this combination, doctors hope to help the immune system better identify and fight any remaining cancer cells.
This trial is for patients with specific types of stage II or III non-small cell lung cancer that has been surgically removed. Participants must not have certain genetic markers (like EGFR or ALK mutations) and will be screened to see if they meet specific health requirements.
You will receive standard chemotherapy combined with pembrolizumab, which is a medicine that helps your immune system fight cancer. The study also involves regular check-ups, including blood tests, imaging scans like MRIs or X-rays, and completing health surveys.
The study is currently recruiting new participants and has sites located in Anchorage, Alaska. You can contact your local oncology team to see if one of these locations is right for you.
- 1Researchers are testing if adding immunotherapy to chemotherapy improves survival after lung cancer surgery.
- 2Pembrolizumab works by helping your own immune system recognize and attack cancer cells.
- 3Participants will be closely monitored with advanced imaging tests and regular check-ups throughout the study.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.